You are here
There are three key publications that support the Tier 2 Non-Admitted Services Classification.
Tier 2 Non-Admitted Services Definitions Manual: This document provides the structural overview of the classification and the definition of each of the Tier 2 classes.
This document provides the technical specifications for how the Independent Hospital Pricing Authority (IHPA) developed the activity based funding models for the service streams to be funded for the National Efficient Price and the National Efficient Cost Determinations 2021–22.
The Independent Hospital Pricing Authority (IHPA) is established under the National Health Reform Act 2011 (Cwlth) (the Act), and by virtue of section 131(1) of the Act is invested with the following functions relevant to this National Efficient Cost Determination 2021–22 (Determination):
The Independent Hospital Pricing Authority (IHPA) is established under the National Health Reform Act 2011 (Cwlth) (the Act), and by virtue of section 131(1) of the Act is invested with the following functions relevant to this National Efficient Price Determination 2021–22 (Determination):
The Pricing Framework for Australian Public Hospital Services 2021–22 (the Pricing Framework) is the key strategic document underpinning the national efficient price (NEP) and national efficient cost (NEC) Determinations for the financial year 2021–22 (NEP21 and NEC21 respectively).
The purpose of the Alterations to the National Pricing Model Framework is to outline the guiding principles and consultative mechanisms that IHPA follows when proposing and implementing changes that materially impact the application of the national funding model.
The National Hospital Cost Data Collection (NHCDC) Report and infographic present the results from the Round 23 NHCDC (financial year 2018–19).
These documents describe the hospital costs submitted by jurisdictions for the following activity streams:
The Governance framework for the development of the admitted care classifications outlines the classification development and approval process, the guiding principles and classification products for the following classifications:
This report was prepared in accordance with the requirements of the National Health Reform Act 2011 and section 46 of the Public Governance, Performance and Accountability Act 2013. The report includes IHPA's audited Financial Statements, as required by section 42 of the Public Governance, Performance and Accountability Act.
The goal of the Consultation and review of the AR-DRG and ICD-10-AM/ACHI/ACS Classification Systems report was to review the end-to-end development processes, implementation arrangements and user needs in developing and implementing updates to the following classifications, now and into the future:
This document guides costing practitioners on the steps to capturing end-to-end COVID-19 activity and expenses under the National Partnership Agreement (NPA). It identifies the principles to be applied, the scope of activity and costs to be funded, cost allocation methods and NPA specific cost centres for cost allocation. This document also introduces two new non-patient products and provides information on how to create and map intermediate products.
National Hospital Cost Data Collection, Data Request Specifications, Round 24 (Financial Year 2019-20)30 July 2020
The National Hospital Cost Data Collection (NHCDC) Data Request Specifications (DRS) contain detailed guidance regarding the submission of Round 24 NHCDC data.
The IHPA Data Compliance Policy describes the process and criteria by which IHPA will publicly report on compliance by jurisdictions with the data requirements and data submission dates specified in the current Three Year Data Plan 2020–21 to 2022–23.
As prescribed in Section 225 of the National Health Reform Act 2011, the objectives of the IHPA Work Program are to:
- set out IHPA’s work program for the coming year; and
- invite interested persons (including states and territories) to make submissions to the Pricing Authority about the Work Program up to 30 days after publication.
An extract of Section 225 of the Act is attached at Appendix 1.
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding18 June 2020
The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.